Introduction
Arbutus Biopharma (ABUS) is one of the many biotech companies focused on the research and development of Hepatitis B therapeutics. What helps make the company stand out from the crowd is its diverse pipeline and financial situation. The company has made great strides in developing a unique RNAi platform and patented lipid nanoparticle delivery technology, which have recently attracted investor dollars, strategic partnerships, and licensing deals.
Arbutus is currently positioned as the clinical leader in RNAi therapeutics for Hepatitis B. The company has been able to demonstrate that its RNAi drug, ARB-1467